Advertisement

Glutamate antagonists modify the motor stimulant actions of D1 and D2 agonists in reserpine-treated mice in complex ways that are not predictive of their interactions with the mixed D1/D2 agonist apomorphine

  • B. S. Starr
  • M. S. Starr
Full Papers

Summary

In 24 h reserpine-treated mice, the locomotion induced by the D1 dopamine agonist SKF 38393 (30 mg/kg IP) was facilitated by the NMDA antagonists MK 801 (0.4 mg/kg IP), CPP (1 mg/kg IP), CGP 40116 (1 mg/kg IP) and HA 966 (2 mg/kg IP), and by the AMPA antagonist NBQX (0.2 mg/kg IP). By contrast, CPP, CGP 40116 and NBQX had no effect on, while MK 801 and HA 966 suppressed, the locomotion elicited by the selective D2 agonist RU 24213 (5 mg/kg SC). When these same doses of glutamate antagonists were tested against the locomotion induced by a threshold (0.025 mg/kg SC), intermediate (0.1 mg/kg SC) or large dose (0.5 mg/kg SC) of the mixed D1/D2 agonist apomorphine, CPP, CGP 40116 and HA 966 were found to have no significant effect, whilst MK 801 was strongly inhibitory and NBQX potentiated the response to 0.1 mg/kg apomorphine only. It is evident from these data that the behavioural interaction profiles between glutamate antagonists and dopamine agonists are complex and depend on the receptor selectivities of the drugs concerned. The manner of the interaction between these glutamate antagonists and selective D1 or D2 agonists, is not predictive of the way that blockade of glutamate transmission interferes with the actions of drugs which have combined D1 and D2 motor stimulant properties.

Keywords

Locomotion mouse reserpine dopamine agonist NMDA antagonist AMPA antagonist 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249: 1436–1438PubMedGoogle Scholar
  2. Carlsson M, Carlsson A (1989a) Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J Neural Transm 77: 65–71CrossRefPubMedGoogle Scholar
  3. Carlsson M, Carlsson A (1989b) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75: 221–226CrossRefPubMedGoogle Scholar
  4. Clark D, White FJ (1987) D1 dopamine receptor—the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications. Synapse 1: 347–388CrossRefPubMedGoogle Scholar
  5. Crossman AR, Peggs D, Boyce S, Luquin MR, Sambrook MA (1989) Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey. Neuropharmacology 28: 1271–1273CrossRefPubMedGoogle Scholar
  6. Davies J, Evans RH, Herrling PL, Jones AW, Olverman HJ, Pook P, Watkins JC (1986) CPP, a new potent and selective NMDA antagonist. Depression of central neuron responses, affinity for [3H]D-AP5 binding sites on brain membranes and anticonvulsant activity. Brain Res 382: 169–173CrossRefPubMedGoogle Scholar
  7. Domino E, Sheng J (1993) N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 interactions in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced hemiparkinsonian monkeys. J Pharmacol Exp Ther 264: 221–225PubMedGoogle Scholar
  8. Euvrard C, Ferland L, Di Paulo T, Beaulieu M, Labrie F, Oberlander C, Raynaud JP, Boissier JR (1980) Activity of two new potent dopaminergic agonists at the striatal and pituitary levels. Neuropharmacology 19: 379–386CrossRefPubMedGoogle Scholar
  9. Fletcher EJ, Lodge D (1988) Glycine reverses antagonism of N-methyl-D-aspartate (NMDA) by 1-hydroxy-3-aminopyrrolidone-2 (HA 966) but not by d-2-amino-5-phosphonovalerate (d-AP5) on rat cortical slices. Eur J Pharmacol 151: 161–162CrossRefPubMedGoogle Scholar
  10. Girault JA, Halpain S, Greengard P (1990) Excitatory amino acid antagonists and Parkinson's disease. Trends Neurosci 13: 325–326CrossRefPubMedGoogle Scholar
  11. Goodwin P, Starr BS, Starr MS (1992) Motor responses to dopamine D1 and D2 agonists in the reserpine-treated mouse are affected differentially by the NMDA receptor antagonist MK 801. J Neural Transm [P-D Sect] 4: 15–26CrossRefGoogle Scholar
  12. Greenamayre JT, O'Brien CF (1991) N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 48: 977–981PubMedGoogle Scholar
  13. Honoré T, Davies SN, Drejer J, Fletcher EJ, Jacobsen P, Lodge D, Nielsen FE (1988) Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science 241: 701–703PubMedGoogle Scholar
  14. Hyttel J (1983) SCH 23390 — the first selective dopamine D-1 antagonist. Eur J Pharmacol 91: 153–154CrossRefPubMedGoogle Scholar
  15. Klockgether T, Turski L (1989) Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease. Trends Neurosci 12: 285–286CrossRefGoogle Scholar
  16. Klockgether T, Turski L (1990) NMDA antagonists potentiate antiparkinsonian actions of L-DOPA in monoamine-depleted rats. Ann Neurol 28: 539–546CrossRefPubMedGoogle Scholar
  17. Klockgether T, Turski L, Honoré T, Zhang Z, Gash DM, Kurlan R, Greenamayre T (1991) The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 30: 717–723CrossRefPubMedGoogle Scholar
  18. Krebs MO, Desce JM, Kemel ML, Gauchy C, Godeheu G, Chéramy A, Glowinski J (1991) Glutamatergic control of dopamine release in rat striatum: evidence for presynaptic N-methyl-D-aspartate receptors on dopaminergic nerve terminals. J Neurochem 56: 81–85PubMedGoogle Scholar
  19. Lieberman A, Neophytides A, Leibowitz M, Kupersmith M, Pact V, Walker R, Zasorin N, Goodgold A, Goldstein M (1980) The use of two new dopamine agonists: pergolide and lisuride in Parkinson's disease. In: Rinne UK, Klingler M, Stamm G (eds) Parkinson's disease: current progress, problems and management. Elsevier, Holland, pp 335–361Google Scholar
  20. Löscher W, Annies R, Hönack D (1991) The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci Lett 128: 191–194CrossRefPubMedGoogle Scholar
  21. Löschmann PA, Lange KW, Kunow M, Rettig KJ, Jähnig P, Honoré T, Turski L, Wachtel H, Jenner P, Marsden CD (1991) Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-DOPA in models of Parkinson's disease. J Neural Transm [P-D Sect] 3: 203–213CrossRefGoogle Scholar
  22. Mitchell IJ, Clarke CE, Boyce S, Robertson RG, Peggs D, Sambrook MA, Crossman AR (1989) Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuroscience 32: 213–226CrossRefPubMedGoogle Scholar
  23. Morelli M, Di Chiara G (1990) MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease. Eur J Pharmacol 182: 611–612CrossRefPubMedGoogle Scholar
  24. Morelli M, Fenu S, Pinna A, Di Chiara G (1992) Opposite effects of NMDA receptor blockade on dopaminergic D1- and D2-mediated behaviour in the 6-hydroxydopamine model of turning: relationship with c-fos expression. J Pharmacol Exp Ther 260: 402–408PubMedGoogle Scholar
  25. Rubinstein M, Gershanik O, Stefano FJE (1988) Different roles of D-1 and D-2 dopamine receptors involved in locomotor activity of supersensitive mice. Eur J Pharmacol 148: 419–426CrossRefPubMedGoogle Scholar
  26. Rubinstein M, Muschietti JP, Gershanik O, Flawia MM, Stefano FJE (1990) Adaptive mechanisms of striatal D1 and D2 dopamine receptors in response to a prolonged reserpine treatment in mice. J Pharmacol Exp Ther 252: 810–816PubMedGoogle Scholar
  27. Schmutz M, Jeker A, Klebs K, Portet C, Pozza M, Fagg GE, Heckendorn R, Allgeier H (1991) CGP 40116/CGP 43487: competitive N-methyl-D-aspartate receptor antagonists with potent oral anticonvulsant activity. Epilepsia 32 [Suppl 1]: 59–60PubMedGoogle Scholar
  28. Seeman P (1981) Brain dopamine recetpors. Pharmacol Rev 32: 229–313Google Scholar
  29. Setler P, Sarau HM, Zirkle CL, Saunders HL (1978) The central effects of a novel dopamine agonist. Eur J Pharmacol 50: 419–430CrossRefPubMedGoogle Scholar
  30. Starr BS, Starr MS (1986) Differential effects of dopamine D1 and D2 agonists and antagonists on velocity of movement, rearing and grooming in the mouse. Neuropharmacology 25: 455–463CrossRefPubMedGoogle Scholar
  31. Starr MS, Starr BS (1993a) Comparison of the effects of NMDA and AMPA antagonists on the locomotor activity induced by selective D1 and D2 dopamine agonists in reserpine-treated mice. Psychopharmacology (in press)Google Scholar
  32. Starr MS, Starr BS (1993b) Facilitation of D1 but not D1/D2-dependent locomotion by glutamate antagonists in the reserpine-treated mouse. Eur J Pharmacol (in press)Google Scholar
  33. Starr BS, Starr MS, Kilpatrick IC (1987) Behavioural role of dopamine D1 receptors in the reserpine-treated mouse. Neuroscience 22: 179–188CrossRefPubMedGoogle Scholar
  34. Svensson A, Carlsson A, Carlsson ML (1992) Differential locomotor interactions between dopamine D1/D2 receptor agonists and the NMDA antagonist dizocilpine in monoamine-depleted mice. J Neural Transm [Gen Sect] 90: 199–217CrossRefGoogle Scholar
  35. Wachtel K, Kunow M, Löschmann PA (1992) NBQX (6-nitro-sulfamoylbenzoquinoxaline-dione) and CPP (3-carboxy-piperazinpropyl-phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats. Neurosci Lett 142: 179–182CrossRefPubMedGoogle Scholar
  36. Wong EHF, Kemp JA (1991) Sites for antagonism on the N-methyl-D-aspartate receptor channel complex. Ann Rev Pharmacol Toxicol 31: 401–425CrossRefGoogle Scholar
  37. Wong EHF, Kemp JA, Priestly T, Knight AR, Woodruff GN, Iversen LL (1988) The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci 83: 7104Google Scholar
  38. Wüllner U, Kupsch A, Arnold G, Renner P, Scheid C, Oertel W, Klockgether T (1992) The competitive NMDA antagonist CGP 40116 enhances L-DOPA response in MPTP-treated marmosets. Neuropharmacology 31: 713–715CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • B. S. Starr
    • 1
  • M. S. Starr
    • 2
  1. 1.Psychology Division, School of Health and Human SciencesUniversity of HertfordshireUK
  2. 2.Department of PharmacologySchool of PharmacyLondonUK

Personalised recommendations